| Balance Sheets | 2025-07-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 10,493,808 | |||
| Short-term investments | 7,372,473 | |||
| Amounts receivable and prepaid expenses | 2,060,295 | |||
| Total current assets | 19,926,576 | |||
| Equity investment in bc therapeutics | 524,278 | |||
| Intangible assets, net | 184,525 | |||
| Property and equipment, net | 296,819 | |||
| Long term prepaid expenses | 717,508 | |||
| Total non-current assets | 1,723,130 | |||
| Total assets | 21,649,706 | |||
| Trade payables | 3,283,703 | |||
| Accrued expenses and other payables | 694,285 | |||
| Total current liabilities | 3,977,988 | |||
| Warrant liability | 337,672 | |||
| Total non-current liabilities | 337,672 | |||
| Share capital of no par value authorized unlimited at july 31, 2025 and 2024 issued and outstanding 1,883,906 and 121,907 shares at july 31, 2025 and 2024, respectively | 101,739,923 | |||
| Share-based payment reserved | 10,316,140 | |||
| Warrant reserve | 17,719,026 | |||
| Accumulated other comprehensive loss | -138,684 | |||
| Non-controlling interest | -546,795 | |||
| Accumulated deficit | -111,755,564 | |||
| Total shareholders equity (deficit) | 17,334,046 | |||
| Total liabilities and shareholders equity (deficit) | 21,649,706 | |||
BriaCell Therapeutics Corp. (BCTXZ)
BriaCell Therapeutics Corp. (BCTXZ)